DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

Information source: Genentech, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergic Asthma

Intervention: Omalizumab (Drug); Placebo (Drug); Asthma therapies (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Genentech, Inc.

Official(s) and/or principal investigator(s):
Clinical Trials, Study Director, Affiliation: Genentech, Inc.


This was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair. In addition, participants who did not participate in the EXCELS study but received long-term (~5 years) treatment with Xolair were allowed to enter the study.

Clinical Details

Official title: A Phase IV, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Persistency of Response With or Without Xolair After Long-term Therapy (XPORT)

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Percentage of Participants Not Experiencing a Protocol-defined Severe Exacerbation During the Study

Secondary outcome: Time to the First Protocol-defined Severe Exacerbation

Detailed description: The treatment designation for participants who reached the primary efficacy endpoint (1 protocol-defined severe asthma exacerbation) was unblinded to allow appropriate clinical intervention. Participants who had their treatment designation unblinded remained in the study for ongoing evaluation of safety and were allowed to continue on study drug known to be Xolair (or to start study drug known to be Xolair if they were in the placebo group).


Minimum age: 17 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria:

- Signed Informed Consent Form (ICF). In the case of a minor, consent must be given by

the child's parent or legally authorized representative.

- Participants who have completed the EXCELS study prior to this study must have met

all inclusion criteria for enrollment in the EXCELS study.

- History of positive skin test or in vitro reactivity to an aeroallergen.

- Continuous Xolair (omalizumab) exposure from the beginning of the EXCELS study to

randomization into this study (if the participant participated in the EXCELS study), or within the previous 5 years prior to randomization into this study (if the participant did not participate in the EXCELS study). For the purposes of this study, continuous Xolair exposure is defined as having missed no more than 25% of scheduled Xolair doses. In addition, a maximum of 2 doses can be missed within the last 6 months before being randomized into this study. For participants who did not participate in the EXCELS study, missed-dose rates will be based on their injection records.

- Patients who participated in the EXCELS study must have completed the EXCELS study

and not discontinued Xolair since the completion of the EXCELS study.

- Diagnosis of moderate to severe persistent allergic asthma while on Xolair as defined

per physician's assessment.

- Stable dosing of current asthma therapies, in addition to Xolair, over 2 months prior

to enrollment.

- Serum IgE level ≥ 30 to ≤ 700 IU/mL before initiation of Xolair treatment (prior to

the EXCELS study enrollment or earlier).

- Body weight ≥ 30 to ≤ 150 kg.

- Treatment with Xolair consistent with the US package insert (USPI) (based on the

dosing table, recommended dose, administration, and dosing interval) prior to enrollment to this study.

- Participants who participated in the EXCELS study must be willing to allow their

EXCELS study data to be used in this study as part of baseline demographic values (such as forced expiratory volume in 1 second [FEV1] and Asthma Control Test [ACT]), as documented in the ICF. Exclusion Criteria:

- Participation in other therapy trials or planned participation during the following

year from screening.

- Contraindication to Xolair therapy (eg, participants who experienced a severe

hypersensitivity reaction to Xolair).

- Acute asthma exacerbation within the 2 months immediately prior to screening that

required any of the following: Initiation of systemic corticosteroids, increased dosing of systemic corticosteroids relative to "stable" dose, doubling of inhaled corticosteroid (ICS) dosing, emergency room visit, and hospitalization.

- Any significant, or unstable, systemic disease (eg, infection, hematologic, renal,

hepatic, cardiovascular diseases, or gastrointestinal diseases), or a recent hospitalization because of systemic disease within the previous 2 months.

- Diagnosis of active lung disease other than asthma.

- Having more than 10 pack-years smoking history.

- Diagnosis of cystic fibrosis.

- Use of an experimental drug within 30 days prior to study screening.

- Unable or unwilling to comply with study procedures and visits (eg, spirometry, blood


- Have elevated serum IgE levels for reasons other than allergy (eg, parasite

infections, hyperimmunoglobulin E syndrome, Wiskott-Aldrich syndrome, or bronchopulmonary aspergillosis).

- Pregnancy, lactation, or any planned pregnancy in the following year.

Locations and Contacts

Huntsville, Alabama 35801, United States

Little Rock, Arkansas 72205, United States

Bakersfield, California 93301, United States

Fresno, California 93720, United States

Fresno, California 93726, United States

Granada Hills, California 91344, United States

Los Angeles, California 90064, United States

Los Angeles, California 90025, United States

Napa, California 94558, United States

Redwood City, California 94063, United States

Sacramento, California 95819, United States

San Francisco, California 94104, United States

San Mateo, California 94401, United States

Studio City, California 91607, United States

Walnut Creek, California 94598, United States

Centennial, Colorado 80112, United States

Thornton, Colorado 80233, United States

Waterbury, Connecticut 06708, United States

Bay Pines, Florida 33744, United States

Clearwater, Florida 33765, United States

Loxahatchee, Florida 33470, United States

Ocala, Florida 34471, United States

Pensacola, Florida 32503, United States

Tampa, Florida 33613, United States

West Palm Beach, Florida 33401, United States

Albany, Georgia 31707, United States

Columbus, Georgia 31904, United States

Gainesville, Georgia 30501, United States

Chicago, Illinois 60612, United States

Glen Carbon, Illinois 62034, United States

Park Ridge, Illinois 60068, United States

Fort Wayne, Indiana 46804, United States

Fort Wayne, Indiana 46815, United States

Overland Park, Kansas 66210, United States

Topeka, Kansas 66606, United States

Lexington, Kentucky 40513, United States

Mandeville, Louisiana 70471, United States

Metairie, Louisiana 70002, United States

Baltimore, Maryland 21236, United States

Ellicott City, Maryland 21042, United States

Gaithersburg, Maryland 20878, United States

Boston, Massachusetts 02114, United States

Gardner, Massachusetts 01440, United States

North Dartmouth, Massachusetts 02747, United States

Taunton, Massachusetts 02780, United States

Liberty, Missouri 64068, United States

Saint Louis, Missouri 63141, United States

Sasint Louis, Missouri 63104, United States

Springfield, Missouri 65807, United States

St Louis, Missouri 63141, United States

St. Louis, Missouri 63110, United States

Bellevue, Nebraska 68123, United States

Omaha, Nebraska 68130, United States

Cranford, New Jersey 07016, United States

Edison, New Jersey 08820, United States

Hillsborough, New Jersey 08844, United States

Verona, New Jersey 07044, United States

Albany, New York 12205, United States

Bronx, New York 10423, United States

Bronx, New York 10461, United States

Bronx, New York 10465, United States

Middletown, New York 10940, United States

Mineola, New York 11501, United States

Mount Vernon, New York 10552, United States

New Paltz, New York 12561, United States

New York, New York 10022, United States

Newburgh, New York 12550, United States

Olean, New York 14760, United States

Rockville Center, New York 11570, United States

Staten Island, New York 10304, United States

Asheville, North Carolina 28801, United States

High Point, North Carolina 27262, United States

Fargo, North Dakota 58103, United States

Fargo, North Dakota 58104, United States

Beaver Creek, Ohio 45434, United States

Centerville, Ohio 45458, United States

Oklahoma City, Oklahoma 73112, United States

Tulsa, Oklahoma 74133, United States

Altoona, Pennsylvania 16601, United States

Beaver, Pennsylvania 15009, United States

Carlisle, Pennsylvania 17013, United States

Harrisburg, Pennsylvania 17110, United States

Pittsburgh, Pennsylvania 15213, United States

Pittsburgh, Pennsylvania 15221, United States

Upland, Pennsylvania 19013, United States

Lincoln, Rhode Island 02865, United States

Greenville, South Carolina 29607, United States

Knoxville, Tennessee 37909, United States

Dallas, Texas 75230, United States

Dallas, Texas 75231, United States

El Paso, Texas 79925, United States

Garland, Texas 75044, United States

Heath, Texas 75032, United States

Round Rock, Texas 78681, United States

San Antonio, Texas 78233, United States

San Antonio, Texas 78251, United States

Richmond, Virginia 23298, United States

Spokane, Washington 99204, United States

Tacoma, Washington 98405, United States

Wheeling, West Virginia 26003, United States

Madison, Wisconsin 53715, United States

Additional Information

Starting date: May 2010
Last updated: October 8, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017